Iltamiocel

依塔麦赛

Report date: 2022/12/23 18:00:22

Base Information

Drug NameIltamiocel
Drug Alias NameAMDC-USRAutologous muscle derived stem cells-Cook MyoSiteCMI-AMDCAMDC-Cook MyoSiteAutologous muscle derived cells-Cook MyoSite +[9] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Muscle-derivedCell and gene therapy > Cell therapy > Somatic cell > Skeletal muscle progenitor cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsStress, PsychologicalLower Urinary Tract SymptomsUrological Manifestations +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesGermany +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCook Myosite Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisCook Myosite Incorporated
Inactive CompaniesN/A
Active IndicationsUrinary Incontinence, StressFecal IncontinenceDeglutition Disorders
Inactive IndicationsStress, PsychologicalLower Urinary Tract SymptomsUrological Manifestations +[6] 

Other Information

ATC CodeN/A
Related LinksN/A